Author:
Hammoud Safaa,Ghoneim Asser
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. doi: 10.1001/jama.288.23.2981
2. Arnett DK, Claas SA, Glasser SP (2006) Pharmacogenetics of antihypertensive treatment. Vasc Pharmacol. doi: 10.1016/jvph.2005.09.010
3. Bozec E, Fassot C, Tropeano AI, Boutouyrie P, Jeunemaitre X, Lacolley P, Dabire H (2003) Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clin Sci 105(5):637
4. Bozkurt O, de Boer A, Grobbee DE, de Leeuw PW, Kroon AA, Schiffers P (2009) Variation in renin–angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens 22:545–551
5. Chobanian AV, Bakris GL, Black HR (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572. doi: 10.1161/01.HYP.0000107251.49515.c2